Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

duce antitumor immunity. J Immunol
2000; 165: 1705±11.
158 Gong J, Avigan D, Chen D,Wu Z,
Koido S, Kashiwaba M, Kufe D. Activation
of antitumor cytotoxic T lymphocytes
by fusions of human dendritic
cells and breast carcinoma cells. Proc
Natl Acad Sci USA 2000; 97: 2715±8.
159 Gong J, Chen D, Kashiwaba M, Li Y,
Chen L, Takeuchi H, Qu H, Rowse GJ,
Gendler SJ, Kufe D. Reversal of tolerance
to human MUC1 antigen in
MUC1 transgenic mice immunized
with fusions of dendritic and carcinoma
cells. Proc Natl Acad Sci USA 1998; 95:
6279±83.
160 Yee C, Thompson JA, Roche P,
Byrd DR, Lee PP, Piepkorn M, Kenyon
K, Davis MM, Riddell SR, Greenberg
PD. Melanocyte destruction after
antigen-specific immunotherapy of
melanoma: direct evidence of t cellmediated
vitiligo. J Exp Med 2000; 192:
1637±44.
161 Stuhler G and Walden P. Recruitment
of helper T cells for induction of
tumor rejection by cytolytic T lymphocytes.
Cancer Immunol Immunother
1994; 39: 342±5.
162 Guo Y,Wu M, Chen H,Wang X, Liu G,
Li G, Ma J, Sy MS. Effective tumor vaccine
generated by fusion of hepatoma
cells with activated B cells. Science
1994; 263: 518±20.
163 Stuhler G, Trefzer U,Walden P.
Hybrid cell vaccination in cancer immunotherapy.
Recruitment and activation
of T cell help for induction of anti
tumour cytotoxic T cells. Adv Exp Med
Biol 1998; 451: 277±82.
164 Satthaporn S, Eremin O. Dendritic
cells (I): biological functions. J R Coll
Surg Edinb 2001; 46: 9±19.
165 Satthaporn S, Eremin O. Dendritic
cells (II): role and therapeutic implications
in cancer. J R Coll Surg Edinb
2001; 46: 159±67.
166 Scott-Taylor TH, Pettengell R,
Clarke I, Stuhler G, La Barthe MC,
Walden P, Dalgleish AG. Human tumor
and dendritic cell hybrids generated
by electrofusion: potential for cancer
vaccines. Biochim Biophys Acta
2000; 1500:2 65±79.
References
167 Trefzer U,Weingart G, Sterry W,
Walden P. Hybrid cell vaccination in
patients with metastatic melanoma.
Methods Mol Med. 2000; 35: 469±75.
168 Tanaka Y, Koido S, Chen D, Gendler
SJ, Kufe D, Gong J. Vaccination
with allogeneic dendritic cells fused to
carcinoma cells induces antitumor immunity
in MUC1 transgenic mice. Clin
Immunol 2001; 101:192±200.
169 Souberbielle BE,Westby M, Ganz S,
Kayaga J, Mendes R, Morrow WJ,
Dalgleish AG. Comparison of four
strategies for tumour vaccination in the
B16-F10 melanoma model. Gene Ther
1998; 5: 1447±54.
170 Dunnion DJ, Cywinski AL,Tucker VC,
Murray AK, Rickinson AB, Coulie P,
Browning MJ. Human antigen-presenting
cell/tumor cell hybrids stimulate
strong allogeneic responses and present
tumor-associated antigens to cytotoxic
Tcells in vitro. Immunology 1999; 98:
541±50.
171 Trefzer U,Weingart G, Chen Y, Herberth
G, Adrian K,Winter H, Audring
H, Guo Y, Sterry W,Walden P.
Hybrid cell vaccination for cancer immune
therapy: first clinical trial with
metastatic melanoma. Int J Cancer
2000; 85: 618±26.
172 Trefzer U, Herberth G, Sterry W,
Walden P. The hybrid cell vaccination
approach to cancer immunotherapy.
Ernst Schering Res Found Workshop
2000; 30: 154±66.
173 Kugler A, Seseke F, Thelen P, Kallerhoff
M, Muller GA, Stuhler G,
Muller C, Ringert RH. Autologous
and allogenic hybrid cell vaccine in patients
with metastatic renal cell carcinoma.
Br J Urol 1998; 82: 487±93.
174 Gilboa E, Nair SK, Lyerly HK. Immunotherapy
of cancer with dendritic-cellbased
vaccines. Cancer Immunol Immunother
1998; 46: 82±7.
175 Ashley DM, Faiola B, Nair S, Hale LP,
Bigner DD, Gilboa E. Bone marrowgenerated
dendritic cells pulsed with tumor
extracts or tumor RNA induce antitumor
immunity against central nervous
system tumors. J Exp Med 1997; 186:
1177±82.
251